In Brief: Rich-Vicks v. Upjohn and McNeil
This article was originally published in The Tan Sheet
Executive Summary
Rich-Vicks v. Upjohn and McNeil: Defendants in patent infringement suit file notice of cross-appeal in U.S. Court of Appeals for the Federal Circuit on Feb. 29. Rich-Vicks filed its notice of appeal on Feb. 6 and has 60 days to submit a brief. Rich-Vicks is attempting to reverse the Jan. 17 decision that its patent for a cough/cold product containing ibuprofen 200 mg/pseudoephedrine 30 mg is not valid and enforceable ("The Tan Sheet" Jan. 22, p. 1)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning